Floatz logo

Alpha-Interferon

Pulmonary Disease, Chronic Obstructive

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Pulmonary Disease, Chronic Obstructive cohort.

Asset / SponsorPhaseRating
Liraglutide
Claus Bogh Juhl
Phase 4BB
Roflumilast
Prince of Songkla University
Phase 3BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Tazobactam
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
20-valent pneumococcal conjugate vaccine
University of Alabama at Birmingham
Phase 4BB

View all 50 →

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
kidney cancerDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →